

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团

Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

POSITIVE PROFIT ALERT

This announcement is made by Meilleure Health International Industry Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and the information currently available to the Company, the Group expects to record a profit attributable to the Shareholders of approximately HK\$18.2 million for the six months ended 30 June 2023 as compared to a profit attributable to the Shareholders of approximately HK\$10.6 million for the six months ended 30 June 2022. Such expected increase is mainly due to the following reasons:

- (i) a significant increase in gross profit from trading business as a result of increase in income from overseas trading;
- (ii) a significant decrease in unrealised fair value losses on investments at fair value through profit or loss as a result of favourable market conditions;
- (iii) a material decrease in share of loss of a joint venture, Shenzhen Wingor Biotechnology Co., Ltd.* (深圳市茵冠生物科技有限公司); partially net off with
- (iv) a material decrease in revaluation gain of investment properties of the Group as well as a decline in gross profit from healthcare-related business as a result of decrease in the sale of healthcare-related products.

The information contained in this announcement is only based on a preliminary assessment by the Board according to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and the information available to the Board as at the date of this announcement, which have not been reviewed, confirmed or audited by the Company's auditors and/or the audit committee and are subject to adjustment. The Company is in the process of preparing and finalising the Group's interim results for the six months ended 30 June 2023. Details of the Group's financial information for the six months ended 30 June 2023 will be disclosed in its interim results announcement which is expected to be published on or before 31 August 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 11 August 2023

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Professor Chau Chi Wai, Wilton, Dr. Yang Yu and Mr. Wu Peng as independent non-executive Directors.

** For identification purposes only*